Physician profile
David S Lilienthal
NPI 1598730921
$6,839.34
in general payments reported to CMS, 2019-2025
43 companies · $668 in 2025
The $668 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $647 · 2021: $1,583 · 2022: $1,575 · 2023: $1,190 · 2024: $1,034 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,408.59 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,004.85 | 2020-2024 | |
| Glaxosmithkline, LLC. | $698.82 | 2019-2025 | Trelegy Ellipta |
| Abbott Laboratories | $648.39 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $584.82 | 2020-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $331.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.04 | 2020-2024 | Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $192.17 | 2020-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $160.41 | 2021-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $126.47 | 2020-2024 | Airsupra |
| Daiichi Sankyo INC. | $124.82 | 2021-2023 | Injectafer |
| Amarin Pharma, INC. | $96.53 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $88.99 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Currax Pharmaceuticals LLC | $87.07 | 2020-2025 | Contrave, Onzetra Xsail |
| Biohaven Pharmaceutical Holding Company LTD. | $80.97 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lilienthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.